Inogen (INGN) Projected to Post Quarterly Earnings on Tuesday

Inogen (NASDAQ:INGN) is projected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Inogen to post earnings of ($0.36) per share and revenue of $82.00 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Inogen Stock Performance

Shares of INGN stock opened at $5.79 on Monday. Inogen has a 1 year low of $5.48 and a 1 year high of $11.94. The firm has a market capitalization of $157.20 million, a PE ratio of -5.73 and a beta of 1.79. The stock has a fifty day moving average of $6.31 and a two-hundred day moving average of $7.27.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $11.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC acquired a new stake in shares of Inogen during the 4th quarter valued at $84,000. Tudor Investment Corp ET AL raised its holdings in shares of Inogen by 10.1% during the fourth quarter. Tudor Investment Corp ET AL now owns 151,602 shares of the medical technology company’s stock worth $1,019,000 after acquiring an additional 13,952 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Inogen during the fourth quarter worth $145,000. Moore Capital Management LP boosted its position in Inogen by 73.5% during the fourth quarter. Moore Capital Management LP now owns 200,005 shares of the medical technology company’s stock valued at $1,344,000 after purchasing an additional 84,696 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in Inogen in the fourth quarter valued at about $86,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.